RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
Apex Bioventures and Dynogen Pharmaceuticals announce definitive merger agreement
Apex Bioventures Acquisition Corp. (AMEX: PEX), a publicly traded special purpose acquisition company with healthcare industry expertise, and
Dynogen Pharmaceuticals, Inc., a privately owned clinical stage biopharmaceutical company focused on gastrointestinal and genitourinary disorders, announced today the signing of a definitive merger agreement.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.